8
1
↑0
↓8
—1
Evidence suggests Semaglutide maydecreaseLean body mass.
8 studies (9 claims)
Emerging evidence
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| semaglutide combined with metformin | Decreases - led to significant reductions | body mass indexes (BMI) | Human | children with simple obesity | Not specified in the abstract. | Acupuncture and moxibustion as effective treatments for simple obesity in children: a meta-analysis. |
| semaglutide | Decreases - more significant reduction | body mass index | Human | Japanese patients with type 2 diabetes | Not specified (doses approved for use in Japan). | Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).cited 9× |
| semaglutide | Decreases - more pronounced body mass index-lowering effects | body mass index | Human | Japanese patients with type 2 diabetes | Not specified (doses approved for use in Japan). | Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).cited 9× |
| semaglutide | Decreases - effectively reduces | body mass index (BMI) | Human | youth with obesity | Once weekly subcutaneous injection (specific dosage not mentioned) | Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.cited 2× |
| semaglutide | Decreases - effectiveness is substantial | body mass index (BMI) | Human | adolescents with obesity aged 12 years and older | Not specified | Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps. |
| Semaglutide | No effect - no significant differences were observed | body mass index (BMI) | Human | patients | — | Comparative effectiveness of semaglutide |
| semaglutide | Decreases - reduced | body mass index | Human | adult with CFRD, obesity, and clinical insulin resistance | — | Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome. |
| semaglutide | Decreases - reduces | placebo-subtracted body mass index mean | Human | adolescents with obesity | — | Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease. |
| once-weekly subcutaneous semaglutide 2.4 mg | Decreases - greater reductions from baseline versus placebo | body mass index | Human | people with obesity | Once-weekly subcutaneous semaglutide 2.4 mg. | Cardiometabolic risk factors efficacy of semaglutide in the STEP program.cited 3× |